Manchester Capital Management LLC bought a new stake in FibroGen Inc (NASDAQ:FGEN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 725 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.

Other large investors have also bought and sold shares of the company. Lindbrook Capital LLC increased its holdings in FibroGen by 150.0% in the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 300 shares during the last quarter. FTB Advisors Inc. purchased a new position in FibroGen in the first quarter valued at $27,000. Meeder Asset Management Inc. increased its holdings in FibroGen by 622.4% in the fourth quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 529 shares during the last quarter. Intercontinental Wealth Advisors LLC purchased a new position in FibroGen in the fourth quarter valued at $37,000. Finally, Cornerstone Advisors Inc. increased its holdings in FibroGen by 672.8% in the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 693 shares during the last quarter. 67.15% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director James A. Schoeneck sold 2,000 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $54.74, for a total transaction of $109,480.00. Following the completion of the sale, the director now owns 29,700 shares in the company, valued at $1,625,778. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Pat Cotroneo sold 14,787 shares of the stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $60.08, for a total transaction of $888,402.96. Following the sale, the senior vice president now owns 267,891 shares of the company’s stock, valued at approximately $16,094,891.28. The disclosure for this sale can be found here. Insiders have sold 271,427 shares of company stock valued at $13,211,151 in the last quarter. Insiders own 8.96% of the company’s stock.

Several equities analysts have issued reports on the company. Mizuho dropped their price objective on FibroGen from $74.00 to $65.00 and set a “positive” rating on the stock in a report on Friday, May 10th. William Blair lowered FibroGen from an “outperform” rating to a “market perform” rating in a report on Friday, May 10th. BidaskClub lowered FibroGen from a “strong-buy” rating to a “buy” rating in a report on Friday, February 22nd. Zacks Investment Research lowered FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. Finally, ValuEngine lowered FibroGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. FibroGen currently has an average rating of “Hold” and a consensus target price of $68.50.

Shares of FGEN stock opened at $35.57 on Friday. The stock has a market cap of $3.06 billion, a price-to-earnings ratio of -34.53 and a beta of 1.60. FibroGen Inc has a 1 year low of $33.51 and a 1 year high of $68.55. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. During the same quarter last year, the company posted ($0.50) earnings per share. The business’s quarterly revenue was down 25.1% compared to the same quarter last year. Analysts predict that FibroGen Inc will post -0.9 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2019/05/25/725-shares-in-fibrogen-inc-fgen-acquired-by-manchester-capital-management-llc.html.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Story: What causes a recession?

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.